Chaperone therapy for Krabbe disease: Potential for late-onset GALC mutations

Journal of Human Genetics

Volumn 60, Issue 9, 2015, Pages 539-545

  Hossain, Mohammad Arif ^a,g   Higaki, Katsumi ^b   Saito, Seiji ^c   Ohno, Kazuki ^d,h   Sakuraba, Hitoshi ^e   Nanba, Eiji ^b   Suzuki, Yoshiyuki ^f   Ozono, Keiichi ^a   Sakai, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c HOKKAIDO INFORMATION UNIVERSITY   (Japan)

^d NPO for the Promotion of Research on Intellectual Property Tokyo   (Japan)

^e MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^f TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^g KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^h ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CHAPERONE; GALACTOSYLCERAMIDASE; N OCTYL 4 EPI BETA VALIENAMINE; UNCLASSIFIED DRUG; HEXOSAMINE; N-OCTYL-BETA-VALIENAMINE;

ARTICLE; CELL LYSATE; COS 1 CELL LINE; ENZYME ACTIVITY; GANGLIOSIDOSIS; GENETIC TRANSFECTION; GLOBOID CELL LEUKODYSTROPHY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MOLECULAR WEIGHT; THERMOSTABILITY; TRANSIENT EXPRESSION; WILD TYPE; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; CHILD; CHLOROCEBUS AETHIOPS; GENETICS; INFANT; LEUKODYSTROPHY, GLOBOID CELL; ONSET AGE; PATHOLOGY; PRECLINICAL STUDY;

ADULT; AGE OF ONSET; ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHILD; COS CELLS; DRUG EVALUATION, PRECLINICAL; GALACTOSYLCERAMIDASE; HEXOSAMINES; HUMANS; INFANT; LEUKODYSTROPHY, GLOBOID CELL; MOLECULAR CHAPERONES;

EID: 84942783562     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2015.61     Document Type: Article

References (32)

1. Wenger, D. A., Escolar, M. L., Luzi, P., & Rafi, M. A. Krabbe disease (globoid cell leukodystrophy), in: Scriver's The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID). Available at http://ommbid.mhmedical.com/content.aspx?bookid=474 & sectionid=45374150 Accessed on 7 March 2014 (2013
2. Sakai, N., Inui, K., Fujii, N., Fukushima, H., Nishimoto, J., Yanagihara, I., et al. Krabbe disease: isolation and characterization of a full-length cDNA for human galactocerebrosidase. Biochem. Biophys. Res. Commun. 198, 485-491 (1994
3. Nagano, S., Yamada, T., Shinnoh, N., Furuya, H., Taniwaki, T., & Kira, J. Expression and processing of recombinant human galactosylceramidase. Clin. Chim. Acta 276, 53-61 (1998
4. Wenger, D. A., Rafi, M. A., & Luzi, P. Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications. Hum. Mutat. 10, 268-279 (1997
5. Hossain, M. A., Otomo, T., Saito, S., Ohno, K., Sakuraba, H., Hamada, Y., et al. Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form. Gene 534, 144-154 (2014
6. Suzuki, K. Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status. Neurochem. Res. 23, 251-259 (1998
7. Escolar, M. L., Poe, M. D., Provenzale, J. M., Richards, K. C., Allison, J., Wood, S., et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N. Engl. J. Med. 352, 2069-2081 (2005
8. Lee, W. C., Courtenay, A., Troendle, F. J., Stallings-Mann, M. L., Dickey, C. A., DeLucia, M. W., et al. Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy. FASEB J. 19, 1549-1551 (2005
9. Lee, W. C., Tsoi, Y. K., Troendle, F. J., DeLucia, M. W., Ahmed, Z., Dicky, C. A., Dickson, D. W., et al. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J. 21, 2520-2527 (2007
10. Ribbens, J., Whiteley, G., Furuya, H., Southall, N., Hu, X., Marugan, J., et al. A highthroughput screening assay using Krabbe disease patient cells. Analyt. Biochem. 434, 15-25 (2013
11. Lee, W. C., Kang, D., Causevic, E., Herdt, A. R., Eckman, E. A., & Eckman, C. B. Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones. J. Neurosci. 30, 5489-5497 (2010
12. Ogawa, S., Matsunaga, Y. K., & Suzuki, Y. Chemical modification of the betaglucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives. Bioorg. Med. Chem. 10, 1967-1972 (2002
13. Iwasaki, H., Watanabe, H., Iida, M., Ogawa, S., Tabe, M., Higaki, K., et al. Fibroblast screening for chaperone therapy in beta-galactosidosis. Brain Dev. 28, 482-486 (2006
14. Higaki, K., Li, L., Bahrudin, U., Okuzawa, S., Takamuram, A., Yamamoto, K., et al. Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency. Hum. Mutat. 32, 843-852 (2011
15. Matsuda, J., Suzuki, O., Oshima, A., Yamamoto, Y., Noguchi, A., Takimoto, K., et al. Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Proc. Natl Acad. Sci. USA 100, 15912-15917 (2003
16. Suzuki, Y., Ichinomiya, S., Kurosawa, M., Matsuda, J., Ogawa, S., Iida, M., et al. Therapeutic chaperone effect of N-octyl 4-epi-β-valienamine on murine GM1-gangliosidosis. Mol. Genet. Metab. 106, 92-98 (2012
17. Lowry, O. H., Rosebrough, N. J., Farr, A. L., & Randall, R. J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951
18. Sali, A., & Blundell, T. L. Comparative protein modeling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815 (1993
19. Trott, O., & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comp. Chem 31, 455-461 (2010
20. Sugawara, K., Tajima, Y., Kawashima, I., Tsukimura, T., Saito, S., Ohno, K., et al. Molecular interaction of imino sugars with human alpha-galactosidase: insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease. Mol. Genet. Metab. 96, 233-238 (2009
21. Tajima, Y., Saito, S., Ohno, K., Tsukimura, T., Tsujino, S., & Sakuraba, H. Biochemical and structural study on a S529V mutant alpha-glucosidase responsive to pharmacological chaperones. J. Hum. Genet. 56, 440-446 (2011
22. Maegawa, G. H., Tropak, M., Buttner, J., Stockley, T., Kok, F., Clarke, J. T., et al. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J. Biol. Chem. 282, 9150-9161 (2007
23. Maegawa, G. H., Tropak, M. B., Buttner, J. D., Rigat, B. A., Fuller, M., Pandit, D., et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 284, 23502-23516 (2009
24. Marugan, J. J., Zheng, W., Motabar, O., Southall, N., Goldin, E., Westbroek, W., et al. Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity. J. Med. Chem. 54, 1033-1058 (2011
25. Motabar, O., Goldin, E., Leister, W., Liu, K., Southall, N., Huang, W., et al. A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide. Anal. Bioanal. Chem. 402, 731-739 (2012
26. Zheng, W., Padia, J., Urban, D. J., Jadhav, A., Goker-Alpan, O., Simeonov, A., et al. Three classes of glucocerebrosidase inhibitors identified by quantitative highthroughput screening are chaperone leads for Gaucher disease. Proc. Natl Acad. Sci. USA 104, 13192-13197 (2007
27. Clarke, J. T., Mahuran, D. J., Sathe, S., Kolodny, E. H., Rigat, B. A., Raiman, J. A., et al. An open-label phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol. Genet. Metab. 102, 6-12 (2011
28. Ishii, S. Pharmacological chaperone therapy for Fabry disease. Proc. Jpn. Acad B 88, 18-30 (2012
29. Mu, T. W., Ong, D. S., Wang, Y. J., Balch, W. E., Yates, J. R., Segatori, L., et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134, 769-781 (2008
30. Deane, J. E., Graham, S. C., Kim, N. N., Stein, P. E., McNair, R., Cachón-González, M. B., et al. Insights into Krabbe disease from structures of galactocerebrosidase. Proc. Natl Acad. Sci. USA 108, 15169-15173 (2011
31. Fu, L., Inui, K., Nishigaki, T., Tatsumi, N., Tsukamoto, H., Kokubu, C., et al. Molecular heterogeneity of Krabbe disease. J. Inher. Metab. Dis 22, 155-162 (1999
32. Conzelmann, E., & Sandhoff, K. Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev. Neurosci. 6, 58-71 (1983